Category: 3. Business

  • Ivonescimab Plus Chemo Might Be a New SOC in Advanced Squamous NSCLC

    Ivonescimab Plus Chemo Might Be a New SOC in Advanced Squamous NSCLC

    Ivonescimab paired with chemotherapy led to a significant improvement in progression-free survival (PFS) vs tislelizumab-jsgr (Tevimbra) plus chemotherapy in patients with advanced squamous non–small cell lung cancer (NSCLC), according to findings from the phase 3 HARMONi-6 study (NCT05840016) presented during the 2025 ESMO Congress.1

    The median PFS was 11.14 months (95% CI, 9.86-not evaluable [NE]) with ivonescimab plus chemotherapy (n = 266) vs 6.90 months (95% CI, 5.82-8.57) with tislelizumab plus chemotherapy (n = 266), translating to a 40% reduction in the risk of disease progression or death (HR, 0.60; 95% CI, 0.46-0.78; P < .0001). The PFS benefit favored ivonescimab plus chemotherapy across all key subgroups.

    “Ivonescimab plus chemotherapy showed significant efficacy improvement with a manageable safety profile and might be a new standard of care for advanced squamous NSCLC,” Shun Lu, MD, PhD, of Shanghai Chest Hospital, in Shanghai, China, said in a presentation of the data during a presidential symposium.

    Top HARMONi-6 Highlights

    • Ivonescimab plus chemotherapy significantly improved PFS to 11.1 vs 6.9 months with tislelizumab (HR, 0.60; P < .0001) in advanced squamous NSCLC.
    • Benefit was observed across PD-L1 subgroups, with higher ORR (75.9% vs 66.5%) and longer median DOR (11.2 vs 8.4 months).
    • Safety remained manageable, with expected immune- and possibly VEGF-related AEs.
    • Findings support ivonescimab as a potential new standard of care in this population.

    In April 2025, Akeso announced that the first-line combination of ivonescimab plus chemotherapy improved PFS in this patient population.2

    What Was Examined in the HARMONi-6 Study?

    The multicenter, double-blind, parallel-controlled study enrolled patients with pathologically confirmed squamous NSCLC who had stage IIIB to IV disease and an ECOG performance status of 0 or 1.1,3 Patients did not have prior exposure to systemic therapy and did not have tumors harboring EGFR mutations or ALK rearrangements.

    Participants (n= 532) were randomly assigned 1:1 to receive ivonescimab at 20 mg/kg every 3 weeks (Q3W) or tislelizumab at 200 mg Q3W plus carboplatin at area under the curve (AUC) 5 Q3W and paclitaxel at 175 mg/m2 Q3W up to 4 cycles followed by ivonescimab at 20 mg/kg Q3W or tislelizumab at 200 mg Q3W for up to 24 months or intolerable toxicity. They were stratified by disease stage (IIIB/IIIC vs IV) and PD-L1 tumor proportion score (TPS; ≥1% vs <1%).

    The primary end point of the study was PFS by independent radiology review committee (IRRC) assessment and RECIST 1.1 criteria, and a key secondary end point was overall survival (OS). Additional secondary end points included investigator-assessed PFS, objective response rate (ORR), disease control rate (DCR), duration of response (DOR), time to response (TTR), and safety.

    A total of 528 patients were planned to provide 86.3% power for PFS assuming PFS HR of 0.70 and 80% power for OS assuming OS HR of 0.73. Investigators leveraged a hierarchical testing approach to evaluate PFS first and OS second—both at a 1-sided α level of 0.025. The presentation delivered at the 2025 ESMO Congress was based on the prespecified PFS interim analysis, which was planned for when 208 PFS events occurred; 221 PFS events were actually observed. The corresponding statistically significant efficacy boundary is P ≤ .0094.

    What Were the Baseline Characteristics of the Patients Enrolled in HARMONi-6?

    In the ivonescimab-plus-chemotherapy arm (n = 266), 49.2% of patients were at least 65 years of age; 47.7% of patients in the tislelizumab/chemotherapy arm (n = 266) were at least 65 years. Most patients in both arms were male (96.2% vs 89.5%), had an ECOG performance status of 1 (84.2% vs 83.5%), were current or former smokers (92.1% vs 86.1%), and had stage IV disease (92.1% vs 92.5%).

    In the ivonescimab arm, 39.5% had a TPS of less than 1%, 60.5% had a TPS of ≥1%, 42.1% had a TPS ranging from 1% to 49%, and 18.4% had a TPS of ≥50%; in the tislelizumab arm, these respective rates were 39.5%, 60.5%, 37.2%, and 23.3%. In the ivonescimab arm, 15.8% of patients had 3 or more metastatic sites, 10.5% had liver metastases, and 3.4% had brain metastases; in the tislelizumab arm, these rates were 14.7%, 16.9%, and 6.4%, respectively.

    What Was the PFS With Ivonescimab in the Different PD-L1 Expression Subgroups?

    Ivonescimab demonstrated meaningful PFS improvement over tislelizumab irrespective of PD-L1 expression. The HR for PFS in those with PD-L1 TPS of under 1% was 0.55 (95% CI, 0.37-0.82); in those with PD-L1 TPS of 1% or higher, the HR for PFS was 0.66 (95% CI, 0.46-0.95). In those with PD-L1 TPS ranging from 1% to 49%, the HR for PFS was 0.63 (95% CI, 0.41-0.98). Lastly, in those with a TPS of 50% or higher, the HR for PFS was 0.71 (95% CI, 0.37-1.33).

    What Additional Ivonescimab Efficacy Data Were Reported?

    In those with any PD-L1 expression, the ORR by IRRC with ivonescimab plus chemotherapy was 75.9% vs 66.5% with tislelizumab plus chemotherapy (P = .008). In the ivonescimab arm, 0.4% of patients had a complete response as best overall response, 75.6% had a partial response, and 14.7% had stable disease; 2.3% had progressive disease. In those with a PD-L1 TPS of less than 1%, the ORRs with ivonescimab were 69.5% vs 61.0% with tislelizumab. In those with a PD-L1 TPS of 1% or higher, these respective rates were 80.1% and 70.2%.

    The median DOR with ivonescimab plus chemotherapy was 11.20 months (95% CI, 8.54-NE) vs 8.38 months (95% CI, 5.72-NE) with tislelizumab plus chemotherapy (P = .0219).

    What Was the Safety Profile of Ivonescimab?

    Treatment-related adverse effects (TRAEs) occurred in 99.2% of patients in the ivonescimab arm vs 98.5% in the tislelizumab arm; they were grade 3 or higher for 63.9% and 54.3%, respectively. Serious TRAEs were experienced by 32.3% of those in the ivonescimab arm and 30.2% of those in the tislelizumab arm. TRAEs led to discontinuation of ivonescimab vs tislelizumab in 3.4% vs 4.2% of patients; 3.0% vs 3.8% of patients experienced TRAEs that led to death.

    The most common TRAEs experienced by at least 15% of patients in the ivonescimab plus chemotherapy arm included alopecia (all grade, 65.4%; grade ≥3, 0%), anemia (53.0%; 6.4%), decreased neutrophil count (45.1%; 32.0%), decreased white blood cell count (36.1%; 10.9%), decreased platelet count (28.6%; 2.6%), hypoesthesia (26.7%; 0%), decreased appetite (21.8%; 1.5%), increased alanine aminotransferase (19.5%; 0.8%), pain in the extremity (18.8% vs 1.1%), proteinuria (18.0%; 1.5%), hypertriglyceridemia (17.3%; 1.1%), increased aspartate aminotransferase (15.8%; 0%), hypoalbuminemia (15.8%), and leukopenia (14.3%; 5.6%), and nausea (14.3%; 0.8%).

    Any-grade immune-related AEs (irAEs) occurred in 27.4% of those in the ivonescimab arm vs 25.3% of those in the tislelizumab arm; they were grade 3 or higher in 9.0% and 10.2% of patients, respectively. Serious irAEs occurred in 8.6% of those who received ivonescimab and 9.8% of those who received tislelizumab. irAEs led to discontinuation of either drug for 1.1% and 2.3% of patients, respectively; 1 patient on the tislelizumab arm experienced an irAE that led to death.

    AEs potentially related to VEGF inhibition occurred more frequently in the ivonescimab arm, and most cases were grade 1 or 2. In the ivonescimab arm, these effects occurred at any grade in 46.2% of patients and at grade 3 or higher in 7.5% of patients; in the tislelizumab arm, these rates were 22.6% and 2.3%, respectively. In the ivonescimab arm, the most common possibly VEGF-related AEs were proteinuria (27.1%; 2.3%), hemorrhage (21.4%; 1.9%), hypertension (10.2%; 3.0%), arterial thromboembolism (1.1%; 1.1%), venous thromboembolism (0.8%; 0%), and fistula (0.4%; 0%).

    What Is the Take-Home Message Regarding Ivonescimab in NSCLC?

    After the presentation, Myung-Ju Ahn, MD, PhD, of the Division of Hematology-Oncology in the Department of Medicine at Samsung Medical Center, Sungkyunkwan University School of Medicine, in Seoul, Korea, commented on the significance of the data. She said: “Ivonescimab plus chemotherapy demonstrates clinically meaningful PFS and ORR across PD-L1 subgroups, with a low rate of hemorrhage even in a population enriched for high-risk features. HARMONi-6 represents an important step forward in the management of squamous NSCLC.”

    She cited the following as important unanswered questions:

    • Real-world application will need multidisciplinary vigilance, especially in those with central tumors or cavitation
    • It is unknown whether PFS benefit will translate into OS benefit. Duration of treatment exposure and post-progression therapy patterns will be important to decipher long-term benefit.
    • Mature OS and quality-of-life data are needed. Angiogenic and immune biomarkers are also needed for patient selection.
    • Global external validation is needed across diverse populations.

    Disclosures: Dr Lu received research support from AstraZeneca, Hutchison, BMS, Heng Rui, Beigene, and Hansoh. Speaker fees were received from AstraZeneca, Roche, Hansoh, and Hengrui Therapeutics. He serves as an advisor and consultant for AstraZeneca, Pfizer, Hutchison MediPharma, ZaiLab, Yuhan Corporation, Menarini, InventisBio Co., Ltd, Shanghai Fosun Pharmaceutical Group Co., Ltd., and Simcere Zaiming Pharmaceutical Co., Ltd. He is an independent board member of Innovent Biologics, Inc.

    References

    1. Lu S, Yang F, Jiang Z, et al. Phase III study of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (HARMONi-6). Presented at: 2025 ESMO Congress; October 17-25, 2025; Berlin, Germany. Abstract LBA4.
    2. Ivonescimab in combination with chemotherapy demonstrates statistically significant and strongly positive results in first-line treatment of squamous non-small cell lung cancer (sq-NSCLC) vs. tislelizumab in combination with chemotherapy. News Release. Akeso. April 23, 2025. Accessed October 19, 2025. https://www.akesobio.com/en/media/akeso-news/250423/
    3. AK112 in combination with chemotherapy in advanced squamous non-small cell lung cancer. ClinicalTrials.gov. May 2, 2025. Accessed October 19, 2025. https://clinicaltrials.gov/study/NCT05840016

    Continue Reading

  • US equity markets finish week higher as tariff threat fades and banks rebound | Wall Street update

    US equity markets finish week higher as tariff threat fades and banks rebound | Wall Street update

    Regional banks drive US market gains

    After a choppy week, the three major United States (US) equity indices finished higher on Friday and for the week. Markets were buoyed as tariff threats faded and regional bank earnings eased credit market concerns. For the week, the Nasdaq 100 finished 2.46% higher, the S&P 500 added 1.70%, and the Dow Jones lifted by 711 points.

    Regional banks rebounded on Friday after several, including Truist Financial, Regions Financial, and Fifth Third, reported better-than-expected earnings. Zions Bancorporation surged 5.8% to $49.67, Truist gained 3.67% to $42.60, Western Alliance added 3.1% to $72.48, and Fifth Third climbed 1.31% to $40.89.

    Despite Friday’s rebound, questions remain about whether last week’s regional bank flare-up is contained or an early sign of broader systemic stress, particularly given the rapid growth in collateralised loan and private credit markets and signs of weaker lending discipline. Thursday’s flare-up followed JPMorgan’s Jamie Dimon warning earlier in the week about ‘cockroaches’ in the credit market after the collapses of Tricolour Holdings and First Brands Group.

    Focus on US-China developments and upcoming tech earnings

    Tariff-related tensions eased into the weekend after US President Trump acknowledged that a 100% tariff on China was unsustainable. It was confirmed he will still meet Chinese President Xi Jinping at the Asia-Pacific Economic Cooperation (APEC) Summit at the end of this month. News that Treasury Secretary Bessent will meet Chinese officials later this week in Malaysia also helped sentiment.

    Looking ahead, attention this week will focus on US-China developments and third quarter (Q3) 2025 earnings from technology companies, including Tesla, Netflix, International Business Machines Corporation, and Intel.

    Despite the US government shutdown entering its fourth week and the Federal Reserve (Fed) now in the blackout period, markets will receive a US inflation update (previewed below).

    Consumer price index 

    Date: Friday, 24 October at 10.30pm AEST

    For August, headline inflation in the US increased by 0.4% in line with expectations. This resulted in the annual rate of headline inflation rising to 2.9%, below the forecast of 3%.

    The annual core consumer price index (CPI), which excludes volatile items like food and energy, rose by 0.3% month-on-month (MoM), which saw the annual core inflation rate remain at 3.1%, unchanged from July and in line with market expectations.

    For September, the expectation is for the annual headline inflation rate to rise to 3.1% year-on-year (YoY), which would be its highest reading since May 2024, while the core measure is expected to remain at 3.1% YoY.

    Ahead of this, the US interest rate market is fully priced for a 25 basis point (bp) Fed cut in October and fully priced for another 25 bp cut in December, as the Fed prioritises bringing support to a cooling labour market despite persistent inflation.

    US core inflation rate chart

    Continue Reading

  • China's new home prices fall at fastest pace in 11 months – Reuters

    1. China’s new home prices fall at fastest pace in 11 months  Reuters
    2. China Home Prices Drop Faster Even as Top Cities Expand Support  Bloomberg.com
    3. China’s property investment falls 13.9% y/y in January-September  TradingView
    4. China’s property slump hits economy as trade tensions with US heighten  The Irish Times
    5. China’s property market poised to decline at least through 2026, S&P analyst says  South China Morning Post

    Continue Reading

  • China’s Decline in Home Sales, Property Investment Worsen

    China’s Decline in Home Sales, Property Investment Worsen

    China’s new home sales by value fell 7.6% in the first nine months from a year earlier, widening from the 7.0% drop in the first eight months, the National Bureau of Statistics said Monday.

    Property investment declined 13.9% over January to September, worsening from the 12.9% decline in the first eight months.

    However, new construction starts by property developers slumped 18.3% in the January-September period versus the 19.5% slide recorded over the first eight months of 2025.

    - - 

    Write to Singapore Editors at singaporeeditors@dowjones.com

    (END) Dow Jones Newswires

    October 19, 2025 22:32 ET (02:32 GMT)

    Copyright (c) 2025 Dow Jones & Company, Inc.

    The articles, information, and content displayed on this webpage may
    include materials prepared and provided by third parties. Such
    third-party content is offered for informational purposes only and
    is not endorsed, reviewed, or verified by Morningstar.

    Morningstar makes no representations or warranties regarding the
    accuracy, completeness, timeliness, or reliability of any third-party
    content displayed on this site. The views and opinions expressed in
    third-party content are those of the respective authors and do not
    necessarily reflect the views of Morningstar, its affiliates, or employees.

    Morningstar is not responsible for any errors, omissions, or delays
    in this content, nor for any actions taken in reliance thereon.
    Users are advised to exercise their own judgment and seek independent
    financial advice before making any decisions based on such content.
    The third-party providers of this content are not affiliated with
    Morningstar, and their inclusion on this site does not imply any
    form of partnership, agency, or endorsement.

    Continue Reading

  • Zurich backs next wave of insurtech talent in global innovation drive

    Zurich backs next wave of insurtech talent in global innovation drive

    At the event, Zurich named 10 winners of the Zurich Innovation Championship 2025, its global competition to find technology solutions that address insurance challenges and improve customer outcomes. Now in its sixth year, the competition reflects Zurich’s push to embed digital innovation and artificial intelligence across underwriting, claims and operations.

    Continue Reading

  • Yen eases as dovish Takaichi set to become Japan PM, Aussie gains – Reuters

    1. Yen eases as dovish Takaichi set to become Japan PM, Aussie gains  Reuters
    2. USD/JPY: US-Japan yield spread breakdown signals further yen strength ahead in the near term  marketpulse.com
    3. Yen’s moving the right way now! Takaichi closer to being PM.  TradingView
    4. Japanese Yen To USD Exchange Rate Hits USD 150.42  inkl
    5. The USD/JPY pair rebounds towards 150.20 as the US Dollar recovers from earlier losses  VT Markets

    Continue Reading

  • Home Prices in China’s Major Cities Continued to Decline in September

    Home Prices in China’s Major Cities Continued to Decline in September

    Home Prices in China’s major cities fell at a slightly faster pace in September from the previous month, highlighting persistent weakness in the nation’s real estate market.

    Average home prices across China’s 70 biggest cities declined 0.41% in September, widening from the 0.3% drop in the previous month, according to calculations by The Wall Street Journal based on data released by the National Bureau of Statistics on Monday.

    Of the 70 cities, 63 reported month-on-month price declines, up from 57 in August.

    On a yearly basis, home prices fell 2.7% in September, compared with a 3.0% drop in August, with 61 cities posting year-over-year declines versus 65 a month earlier.

    For the first nine months of the year, average home prices in the 70 major cities were down 4.1% from a year earlier.

    Write to Singapore editors at singaporeeditors@dowjones.com

    (END) Dow Jones Newswires

    October 19, 2025 22:04 ET (02:04 GMT)

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading

  • MENA’s innovation map expands as Syria debuts, Palestine rises at GITEX 2025

    MENA’s innovation map expands as Syria debuts, Palestine rises at GITEX 2025

    At this year’s GITEX Global, the region’s largest technology exhibition, the spotlight quietly shifted to two pavilions that told a different kind of story. At Expand North Star, the startup-focused arm of GITEX held at Dubai Harbour, Syria made its first-ever appearance, and Palestinian founders drew a surge of investor interest.

    The event, which ran for four days and brought together thousands of startups and more than a thousand investors, has become the region’s ultimate deal-making arena, a space where “let’s meet” often turns into “let’s sign.” Amid the bustle of global pitches and product launches, Syria’s debut and Palestine’s growing presence stood out as signals of resilience, recovery, and quiet ambition.

    Syria is back on centre stage

    Conversations were lively inside the Syrian pavilion. Entrepreneurs who had spent years abroad were meeting international investors face to face, many for the first time. The pavilion was hosted by SYNC, a California-based, volunteer-led non-profit founded by members of the Syrian tech diaspora to help rebuild the country’s innovation ecosystem.

    “Our goal is to mobilise Syrian tech talent in the diaspora and connect them with opportunities back home,” said Firas Khalifeh, SYNC’s co-founder, speaking to Wamda. “We want to create 25,000 tech jobs in Syria within five years and start reversing the brain drain that has hollowed out our workforce.”

    Two Syrian founders—Rahaf Aldruby and Seem Alkabbani—offered a glimpse of that ambition when their edtech startup TarKeys won an $8,000 grant from TiE Dubai after pitching at Expand North Star. Their success symbolised a new chapter for Syrian entrepreneurship: talent that had survived years of turmoil now competing on the global stage.

    A country rebuilding from zero

    Following the fall of Bashar al-Assad’s regime in December 2024, Syria has entered an uncertain but potentially transformative phase. Almost every sector—infrastructure, finance, education, and healthcare— requires rebuilding. With roughly 40 percent of sanctions lifted and the rest expected to ease by year’s end, the government and private sector see a window to re-enter global markets.

    “It’s a big risk, I know, for investors to deploy their funds in Syria,” Khalifeh said. “But first movers will benefit from the potential of a hungry market like ours. The time is now to use this opportunity.”

    At GITEX, Syria’s Minister of Communications and Information Technology, Abdulsalam Haykal, met with entrepreneurs and outlined a plan to restore digital infrastructure. “Connectivity and electricity come first,” he said, emphasising that his ministry is working with the Ministry of Finance on new legislation to govern venture capital activity and launch incubators and accelerators for early-stage startups. His presence was more than symbolic; it underscored that Syria’s tech revival now has political backing.

    Why Syria’s comeback matters to MENA

    When Syria was cut off from the region’s tech revolution a decade ago, the MENA ecosystem lost scale, talent, and balance.

    Before the war, Syrian universities produced a steady stream of engineers, developers, and designers. Many ended up in GCC economies or Europe, and when the conflict began, the flow became one-way. The region lost a mid-cost, high-skilled labour corridor that could have bridged the gap between North Africa’s affordability and the Gulf’s capital intensity.

    Syria’s exit also fractured digital supply chains across the Levant. Companies were forced to reroute their logistics and connectivity around the missing link between Iraq, Jordan, Lebanon, and Turkey. A domestic market of 22 million consumers, once a potential testing ground for fintech and e-commerce, effectively vanished. And while Syrian professionals thrived abroad, their experience rarely flowed back into the regional pipeline.

    Now, with sanctions easing and the economy reopening, MENA stands to regain that lost piece. Syria’s reintegration could create a new reservoir of affordable, skilled talent, particularly in software, AI, and remote engineering, fields that Gulf and Levant firms struggle to fill.

    Its electronics base and low operating costs could make it a new node for light manufacturing and deep-tech assembly—what Khalifeh calls “China of the Levant”. Projects like SilkLink, a proposed high-speed internet corridor linking Asia to Europe through Syria, could strengthen regional connectivity and reduce data costs.

    For investors, Syria’s re-entry expands the region’s consumer and entrepreneurial map, adding a digitally literate market with strong remittance inflows and diaspora purchasing power. Jordanian, Lebanese, and Saudi VCs are already eyeing early-stage opportunities, betting on high risk but potentially high reward.

    Palestine: building through adversity

    Across the exhibition hall, the Palestinian delegation delivered one of the event’s most emotional and determined performances. It was the third consecutive year for Palestinian entrepreneurs at GITEX, this time supported by European partners, Bank of Palestine, and private firms such as Profarco.

    Rateb Rabie, CEO of Intersect, has attended several editions of the event. “I don’t know how to tell you what the benefit of joining GITEX this year is,” he said with a laugh. “Many investors passed today — Lebanese, international, and several UAE funds. We ran an extensive outreach campaign on social media, and our startups joined panels to introduce themselves. The feedback has been positive, maybe still lip service, but it’s a start.”

    By the third day, activity had surged. Seven to eight startups were continuously giving interviews, and several were featured in Expand North Star’s publicity. Foot traffic increased as visitors moved between three Palestinian pavilions. In total, 33 Palestinian startups showcased products spanning agritech, AI, SaaS, and creative industries.

    “These are thirty-three stars,” Rabie said proudly. “Thirty-three Palestinians, in a circle.”

    The symbolism is profound. These founders are pitching for capital and visibility while their homeland faces one of the deadliest conflicts in modern history. By early October 2025, independent monitors estimated that more than 67,000 Palestinians had been killed and nearly 169,000 injured in Gaza. Infrastructure is devastated, yet Palestinian entrepreneurs continue to show up, not out of denial, but defiance.

    Dubai’s role as a regional bridge

    For both delegations, Dubai offered more than visibility. The city’s regulatory clarity, investor depth, and geographic neutrality make it a natural meeting point for governments, diaspora leaders, and global corporates. Expand North Star was designed for exactly this—dense investor traffic, fast deal cycles, and a platform to integrate newcomers into the regional startup circuit.

    The presence of Syria and Palestine this year added substance to what can often feel like a marketplace of trends. Syria brought the optimism of reconstruction and reintegration; Palestine brought courage under fire. Both reminded investors that innovation often comes from the margins, where necessity breeds the strongest ideas.

    The bottom line

    MENA’s startup story has often been told through the Gulf’s capital and North Africa’s scale. The return of Syria and the persistence of Palestine add missing dimensions: engineering depth, creative grit, and human resilience.

    If investors are serious about long-term regional diversification, this is where the next wave begins, in countries rebuilding their foundations and rewriting their narratives through technology. The opportunity is clear. The challenge, as always, is who dares to move first.

    Continue Reading

  • Dow Jones Top Markets Headlines at 9 PM ET: Stock Futures Rise Ahead of Major Week of Earnings | Luxury …

    Dow Jones Top Markets Headlines at 9 PM ET: Stock Futures Rise Ahead of Major Week of Earnings | Luxury …

    Stock Futures Rise Ahead of Major Week of Earnings

    The economic highlight of the week will be the September consumer price index, coming out on Friday.

    —-

    Luxury Brands’ Stiffest Competition Is the Stuff They Have Already Sold

    Sales of secondhand luxury goods are growing faster than in brands’ own stores.

    —-

    A New Challenge for China’s Economy: ‘Involution’

    Beijing is fighting to limit the damage from a pattern of price wars and excess capacity across multiple industries.

    —-

    Is Gold in the Grips of a Speculative Bubble?

    The danger is that gold is in the grip of the sort of speculative excess that creates bubbles in other parts of the financial system.

    —-

    Week Ahead for FX, Bonds: U.S. Inflation, PMI Data in Focus as Shutdown Continues

    Delayed U.S. inflation data are due to be released during the week and will attract attention from investors seeking evidence on the likelihood of future interest-rate cuts.

    —-

    Unemployment Claims Filed by Federal Workers Shoot Higher

    Data from states show that initial unemployment claims filed by federal government workers have jumped up this month.

    —-

    Banks’ Strong Earnings Leave Investors Digging Deeper for Trouble Spots

    Earnings from the country’s biggest banks show a booming Wall Street and a solid consumer. But a warning from Jamie Dimon took center stage.

    —-

    Bank of Canada Survey, CPI Data to Weigh on Next Rate Decision, Gov. Macklem Says

    The central bank’s quarterly business-outlook survey and September’s consumer-price index data are slated for release next week.

    —-

    BOE Should Show More Caution in Future Rate Cuts, Says Chief Economist

    The BOE’s Huw Pill called for the pace of cuts to be slowed in recognition of stubborn high inflation.

    —-

    Venezuela Mobilizes Troops and Militias as U.S. Military Looms Offshore

    Nicolás Maduro says his country is ready for combat, though the strongman’s military is underfunded, ill-trained and no match for American firepower.

    —-

    Gold Stocks Are Surging. They Still Lag Behind Cold, Hard Bullion.

    Since the start of August, a fresh rush into gold has fed demand for gold equities, whose gains have outpaced chip stocks riding the artificial-intelligence boom.

    —-

    China’s Communist Elites Gather to Map Strategy

    A communique after the Communist Party’s Central Committee meeting, which runs Monday to Thursday, will indicate how Beijing aims to steer the economy through turbulence, though details of its 15th five-year plan won’t be released until March.

    (END) Dow Jones Newswires

    October 19, 2025 21:15 ET (01:15 GMT)

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading

  • Oil prices slip on concerns over US-China trade tensions

    Oil prices slip on concerns over US-China trade tensions

    TOKYO, Oct 20 (Reuters) – Oil prices dipped on Monday, pressured by worries over a global glut as escalating U.S.-China trade tensions added to concerns about an economic slowdown and weaker energy demand.

    Brent crude futures fell 24 cents, or 0.4%, at $61.05 a barrel at 0032 GMT, while U.S. West Texas Intermediate futures were down 21 cents, or 0.4%, at $57.33, erasing gains from Friday.

    Sign up here.

    Both benchmarks declined more than 2% last week, marking their third consecutive weekly decline, partly due to the International Energy Agency’s outlook for a growing supply glut in 2026.

    “Concerns about oversupply from increased production by oil- producing nations, coupled with fears of an economic slowdown stemming from escalating U.S.-China trade tensions, are fuelling selling pressure,” said Toshitaka Tazawa, an analyst at Fujitomi Securities.

    “While the U.S. is stepping up pressure on buyers of Russian crude, the upcoming summit between U.S. President Donald Trump and Russian President Vladimir Putin adds uncertainty to the outlook, making it difficult for some investors to adjust their positions,” he said.

    Last week, the head of the World Trade Organization said she had urged the U.S. and China to de-escalate trade tensions, warning that a decoupling by the world’s two largest economies could reduce global economic output by 7% over the longer term.
    The two top oil consumers have recently renewed their trade war, imposing additional port fees on ships carrying cargo between them – tit-for-tat moves that could disrupt global freight flows.

    Meanwhile, Trump and Putin agreed on Thursday to hold another summit on the war in Ukraine, even as Washington pressured India and China to stop buying Russian oil.

    Following talks with Ukrainian President Volodymyr Zelenskiy at the White House on Friday, Trump implored both Ukraine and Russia to “stop the war immediately,” even if it means Ukraine conceding territory.
    U.S. and European pressure on Asian buyers of Russian energy could restrict India’s oil imports from December, leading to cheaper supplies for China, trade sources and analysts said.
    On the supply side, U.S. energy firms last week added oil and natural gas rigs for the first time in three weeks, energy services firm Baker Hughes (BKR.O), opens new tab said in its closely followed report on Friday.

    Reporting by Yuka Obayashi; Editing by Sonali Paul

    Our Standards: The Thomson Reuters Trust Principles., opens new tab

    Continue Reading